Brian K. Fiske, Ph.D.
Affiliations: | 2004- | Research Programs | The Michael J. Fox Foundation for Parkinson's Research |
Area:
Olfaction, Brain Development, Parkinson's diseaseGoogle:
"Brian Fiske"Mean distance: 15.05 (cluster 6) | S | N | B | C | P |
Parents
Sign in to add mentor| Peter C. Brunjes | grad student | 1995-2000 | UVA | |
| (Cell death during olfactory bulb development.) | ||||
| Lloyd Greene | post-doc | 2000-2001 | Columbia University Medical School | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McFarthing K, Buff S, Rafaloff G, et al. (2023) Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. Journal of Parkinson's Disease. 13: 427-439 |
| Frasier M, Fiske BK, Sherer TB. (2022) Precision medicine for Parkinson's disease: The subtyping challenge. Frontiers in Aging Neuroscience. 14: 1064057 |
| Lungu C, Cedarbaum JM, Dawson TM, et al. (2021) Seeking progress in disease modification in Parkinson disease. Parkinsonism & Related Disorders |
| Lai D, Alipanahi B, Fontanillas P, et al. (2021) Genome-wide association studies of LRRK2 modifiers of Parkinson's disease. Annals of Neurology |
| Simuni T, Fiske B, Merchant K, et al. (2020) Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. Jama Neurology |
| Grenn FP, Kim JJ, Makarious MB, et al. (2020) The Parkinson's Disease Genome-Wide Association Study Locus Browser. Movement Disorders : Official Journal of the Movement Disorder Society |
| Padmanabhan S, Fiske BK, Baptista MAS. (2020) The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. Cells. 9 |
| Barker RA, Bjorklund A, Gash DM, et al. (2020) GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease |
| Baptista MAS, Merchant K, Barrett T, et al. (2020) LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Science Translational Medicine. 12 |
| Padmanabhan S, Polinski NK, Menalled LB, et al. (2019) The Michael J. Fox Foundation for Parkinson's Research Strategy to Advance Therapeutic Development of PINK1 and Parkin. Biomolecules. 9 |